QCLS
Q/C Technologies, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Q/C Technologies, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
No thesis.
—
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; no measured co-movers for Q/C Technologies, Inc..
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; no measured co-movers for Q/C Technologies, Inc..
—
Largest filed tie
—
—
—
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Quinn Opportunity Partners | $479,794 | 16.70% | −41.80% |
| Vanguardindex-like | $448,621 | 15.61% | +206.66% |
| Jane Street | $340,240 | 11.84% | −30.86% |
| Geodeindex-like | $275,659 | 9.59% | +49.15% |
| UBS | $229,686 | 7.99% | −24.48% |
| Manager | Value | % base | |
|---|---|---|---|
| Quinn Opportunity Partners | $479,794 | 16.70% | −41.80% |
| Vanguardindex-like | $448,621 | 15.61% | +206.66% |
| Jane Street | $340,240 | 11.84% | −30.86% |
| Geodeindex-like | $275,659 | 9.59% | +49.15% |
| UBS | $229,686 | 7.99% | −24.48% |
+3.59%
shares held · 10 largest managers
Q/C Technologies, Inc.
0.42
0.00 · +0.71%